Is genomic data the new frontier in drug discovery?

<p>This is the latest episode of the free DDW podcast, “Is genomic data the new frontier in drug discovery?”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “<a href= "https://www.ddw-online.com/genomics-boosts-understanding-of-covid-19-severity-and-susceptibility-15240-202201/">Genomics boosts understanding of Covid-19 severity and susceptibility</a>” and “<a href= "https://www.ddw-online.com/rare-variant-contribution-to-human-disease-15272-202201/">Rare variant contribution to human disease</a>”.</p> <p>The Covid-19 Host Genetics Initiative carried out one of the largest genome-wide association studies ever. In the first article, Dr Hamdi Mbarek, Lead Analyst of the Qatari dataset, explains how the initiative improved knowledge of host-genetic determinants of Covid-19 infection and severity.</p> <p>In the second article, Slavé Petrovski and Andrew Harper, from the Centre for Genomics Research at AstraZeneca, outline the implications and insight offered by the recent publication of an AstraZeneca-authored paper “Rare variant contribution to human disease in 281,104 UK Biobank exomes”.</p>